Mr. Rudnick is the founder and Managing Partner of CapGenic Advisors, LLC, Chief Business Officer of NovoBioPharma, and a member of several angel groups. Mr. Rudnick’s entrepreneurial career includes several start-ups, three of which grew to over $60 million in revenue. He is a founder of one of the nation’s leading entrepreneurial programs (MADV) at the Fox School of Business, a director of Otosound, director and CFO of Immunomic Therapeutics, and has held several other board positions. With over 30 years of experience in executive-level strategy, finance, and management, Mr. Rudnick has senior merger, acquisition, capital formation and licensing leadership experience with companies ranging from start-up to Fortune 50. Mr. Rudnick currently advises companies in clinical software, therapeutic, medical device, and cell line engineering areas. His angel group affiliations include Minority Angel Investment Network, a founder of Mid-Atlantic Bio Angels and Keiretsu Mid-Atlantic.